Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Fiona Simpkins, M.D.

Fiona Simpkins, M.D.

faculty photo
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
B.S. (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
(Molecular Signaling Section, Cancer Research Training Fellowship)
NIH, NCI, 2005.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F.: MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res in press, Oct 2015.

Garcia-Soto A, McKenzie N, Portelance L, Castillo R, Pearson M, Hu J, Lucci JA 3rd, Lin L, Simpkins F: Phase I trial of nelfinavir added to cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. J Clin Oncol 33 (suppl; abstr TPS5619), Oct 2015.

Zhang X, Haggerty AF, Brown JC, Giuntoli R 2nd, Lin L, Simpkins F, Dean LT, Ko E, Morgan MA, Schmitz KH: The prescription or proscription of exercise in endometrial cancer care. Gynecol Oncol 139(1):155-9, Oct 2015.

Cui H, He Y, Krepler C, Tanyi J, Morgan MA, Burger RA, Kim S, Ko E, Ince T, Herlyn M, Simpkins F: A true orthotopic ovarian cancer patient-derived xenograft (PDX) model. Cancer Res 75; 3223, August 2015.

Simpkins F, Hew K, Azzam D, Wei Z, Zhang G, Sun J, Zhang D, Jang K, Liu W, Lu Y, Mills G, Tan I, Slingerland J: Combined Src and MEK inhibition decreases ovarian cancer (OVCA) cell growth, tumorigenicity and aldehyde dehydrogenase positive tumor-initiating-cells. Clin Cancer Res 21; POSTER-THER-1431, August 2015.

Hew K, Miller P, Sun J, Wei Z, Zhang G, Lu Y, Mills G, Slingerland J, El-Ashry D, Simpkins F: MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/estrogen regulated gene expression. Clin Cancer Res 21; AS31, August 2015.

Chen J, Solomides C, Parekh H, Simpkins F, Simpkins H: Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemother Pharmacol 75(6):1217-27, Jun 2015.

Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N2, Rose PG: A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol 136(2):240-5, Feb 2014.

Schroeder E, De La Garza J, Wrenn D, Simpkins F, Pearson M, Diaz J: Cost-effectiveness analysis used of four chemotherapy regimens used in the treatment of platinum-sensitive recurrent epithelial ovarian carcinoma. Published as abstract for the SGO meeting. Gynecology Oncology 133 (2014) 2-207, 2014.

Schroeder E, Burbano-Levy X, De La Garza J, Garcia-Soto A, Hew A, Simpkins F, Lucci JA 3rd, Diaz J: Is the survival advantage of bevacizumab added to chemotherapy for the treatment of recurrent cervix cancer worth the additional cost? Published as abstract for the SGO meeting. Gynecology Oncology 133 (2014) 2-207, 2014.

back to top
Last updated: 01/24/2016
The Trustees of the University of Pennsylvania